Sequoia Financial Advisors LLC Acquires 78,626 Shares of Pfizer Inc. (NYSE:PFE)

Sequoia Financial Advisors LLC lifted its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 28.3% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 356,705 shares of the biopharmaceutical company's stock after acquiring an additional 78,626 shares during the period. Sequoia Financial Advisors LLC's holdings in Pfizer were worth $9,039,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the stock. Rialto Wealth Management LLC acquired a new position in Pfizer during the fourth quarter valued at approximately $26,000. Clarity Asset Management Inc. acquired a new stake in shares of Pfizer in the fourth quarter worth $27,000. Gould Capital LLC lifted its stake in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares during the last quarter. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer during the 4th quarter worth $28,000. Finally, Bernard Wealth Management Corp. acquired a new position in Pfizer in the 4th quarter valued at $30,000. 68.36% of the stock is owned by institutional investors.

Analysts Set New Price Targets

PFE has been the subject of a number of research analyst reports. Citigroup reissued a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $25.00 price objective (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, UBS Group upped their price target on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Stock Performance

Pfizer stock traded down $0.04 during trading hours on Friday, hitting $24.20. The stock had a trading volume of 39,502,107 shares, compared to its average volume of 41,288,221. The company has a 50-day moving average of $23.42 and a two-hundred day moving average of $24.85. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The company has a market cap of $137.56 billion, a PE ratio of 17.53, a price-to-earnings-growth ratio of 0.88 and a beta of 0.57.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. Pfizer's quarterly revenue was down 7.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.82 earnings per share. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.11%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio is 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.